Target intelligence / Profile preview

Paracrine factor release

Molecular classification
Cell signaling process, Intercellular communication
01

Overview

Paracrine factor release is a fundamental biological process where a cell secretes signaling molecules, known as paracrine factors, into the immediate extracellular environment to induce changes in nearby neighboring cells. Unlike endocrine signaling, which involves hormones traveling through the bloodstream, paracrine signaling is localized and critical for maintaining tissue homeostasis, coordinating immune responses, and directing embryonic development. In the context of therapeutics, this process is frequently discussed regarding the 'paracrine hypothesis' of stem cell therapy, suggesting that transplanted cells promote healing primarily by secreting factors rather than direct differentiation. However, dysregulated paracrine signaling is a hallmark of many diseases; for instance, in the tumor microenvironment, cancer cells and associated stroma exchange factors that promote angiogenesis, immune evasion, and metastasis. Because 'Paracrine factor release' describes a broad physiological mechanism rather than a specific protein, enzyme, or receptor, it is not considered a discrete therapeutic target in drug discovery, although many specific molecules involved in this process are highly validated targets.

Other names
Liberación de factores paracrinosParacrine signalingParacrine secretionParacrine effect
02

Mechanism of action

Modulation of the production, secretion, or reception of signaling molecules that act on neighboring cells to alter their behavior or environment.

03

Biological functions

Signal transductionCell-to-cell communicationTissue repairInflammationGrowth regulationAngiogenesis
04

Disease associations

CancerInflammationCardiovascular diseaseTissue fibrosisAutoimmune disorders
05

Safety considerations

Systemic toxicity from disrupting local signaling pathwaysOff-target effects in healthy tissuesImpaired wound healingPotential for promoting tumor growth if improperly modulated
06

Interacting drugs

Bevacizumab (targets VEGF)

2 more in the full profile.

07

Biomarkers

Vascular endothelial growth factor (VEGF)Interleukin-6 (IL-6)Transforming growth factor beta (TGF-beta)Fibroblast growth factor (FGF)

Beyond the preview

Go deeper on Paracrine factor release.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paracrine factor release.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call